1. Home
  2. CANF vs SHPH Comparison

CANF vs SHPH Comparison

Compare CANF & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$4.23

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.43

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
SHPH
Founded
1994
2012
Country
Israel
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
2.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CANF
SHPH
Price
$4.23
$1.43
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9,750.00
N/A
AVG Volume (30 Days)
555.6K
494.6K
Earning Date
02-03-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
N/A
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.36
$1.26
52 Week High
$46.60
$25.25

Technical Indicators

Market Signals
Indicator
CANF
SHPH
Relative Strength Index (RSI) N/A 39.19
Support Level N/A $1.29
Resistance Level N/A $2.73
Average True Range (ATR) 0.00 0.28
MACD 0.00 -0.03
Stochastic Oscillator 0.00 12.50

Price Performance

Historical Comparison
CANF
SHPH

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: